Evidence map›Paper›PMID 39534510›Full record

ArticlePulmonary circulation2024

Infection and pulmonary vascular diseases consortium: United against a global health challenge.

S D Oliveira, S Almodóvar, G Butrous, V De Jesus Perez, A Fabro, B B Graham, A Mocumbi, P S Nyasulu, O Tura-Ceide, R K F Oliveira and 2 more

Abstract read
In one paragraph

Article in Pulmonary circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Endothelial c-IAP2 loss amplifies P2X7 receptor-driven inflammation and worsens schistosomiasis-associated pulmonary hypertension.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

S D OliveiraVascular Immunobiology Lab, Department of Anesthesiology, Department of Physiology and Biophysics, College of Medicine University of Illinois Chicago Chicago Illinois USA.ORCID 0000-0002-7654-1909
S AlmodóvarDepartment of Immunology & Molecular Microbiology Texas Tech University Health Sciences Center, School of Medicine Lubbock Texas USA.
G ButrousMedway School of Pharmacy University of Kent Medway Kent United Kingdom.
V De Jesus PerezDivision of Pulmonary and Critical Care Stanford University Palo Alto California USA.
A FabroDivision of Respiratory Diseases Federal University of São Paulo Sao Paulo Brazil.
B B GrahamDepartment of Medicine, Zuckerberg San Francisco General Hospital University of California San Francisco San Francisco California USA.ORCID 0000-0001-7541-2585
A MocumbiDepartment of Medicine Universidade Eduardo Mondlane Maputo Mozambique.
P S NyasuluDepartment of Global Health, Faculty of Medicine & Health Sciences Stellenbosch University Cape Town South Africa.
O Tura-CeideBiomedical Research Institute-IDIBGI Girona Spain.
R K F OliveiraDivision of Respiratory Diseases, Department of Medicine Federal University of São Paulo (Unifesp) São Paulo Brazil.
N K DhillonDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine University of Kansas Medical Center Kansas City Kansas USA.
Infection and Pulmonary Vascular Diseases Consortium

Funding

Role of Complement-Driven Pulmonary Vascular Inflammation in PHP01HL152961 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI TUDER, RUBIN M. · 2020 to 2024
$14.1M
Investigating paclitaxel treatment in a pre-clinical model of Schistosoma-pulmonary hypertensionR01HL135872 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Brian Barkley Graham · 2017 to 2026
$5.1M
Drug abuse and HIV-associated pulmonary vascular injuryR01HL152832 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI DHILLON, NAVNEET KAUR · 2021 to 2024
$2.8M
Role of HIV gp120 and Nef in Transcriptome Dysregulation and Pulmonary Vascular RemodelingR01HL172709 · NHLBI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI SHARILYN ALMODOVAR · 2024 to 2026
$2.1M
Diffuse optical spectroscopies to assess cerebral hemodynamics in pediatric sickle cell diseaseR01HL152322 · NHLBI · EMORY UNIVERSITY · PI BUCKLEY, ERIN MCGUIRE, GEE, BEATRICE E · 2021 to 2024
$2.0M
Generation of Endothelial Cell Memory in Inflammatory Vascular DiseaseK01HL159037 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DOS SANTOS OLIVEIRA, SUELLEN D'ARC · 2021 to 2025
$800k
Screening for schistosomiasis-associated pulmonary arterial hypertensionR21AI171968 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAHAM, BRIAN BARKLEY, HILTON, JOAN F · 2023 to 2024
$465k
NHLBI NIH HHS K01 HL159037NHLBI NIH HHS P01 HL152961NHLBI NIH HHS R01 HL135872NHLBI NIH HHS R01 HL152322NHLBI NIH HHS R01 HL152832NHLBI NIH HHS R01 HL172709NIAID NIH HHS R21 AI171968
6 · The paper itself

Abstract

Leveraging the potential of virtual platforms in the post-COVID-19 era, the Infection and Pulmonary Vascular Diseases Consortium (iPVDc), with the support of the Pulmonary Vascular Research Institute (PVRI), launched a globally accessible educational program to highlight top-notch research on inflammation and infectious diseases affecting the lung vasculature. This innovative virtual series has already successfully brought together distinguished investigators across five continents - Asia, Europe, South and North America, and Africa. Moreover, these open global forums have contributed to a comprehensive understanding of the complex interplay among immunology, inflammation, infection, and cardiopulmonary health, especially concerning pulmonary hypertension and related pulmonary disorders. These enlightening discussions have not only heightened awareness about the impact of various pathogenic microorganisms, including fungi, parasites, and viruses, on the onset and development of pulmonary vascular diseases but have also cast a spotlight on co-infections and neglected illnesses like schistosomiasis - a disease that continues to impose a heavy socioeconomic burden in numerous regions worldwide. Thus, the overall goal of this review article is to present the most recent breakthroughs from infectious PVDs as well as bring to light the scientific and educational insights from the 2023 iPVDc/PVRI virtual symposium series, shaping our understanding of these crucial health issues in this more than ever interconnected world.

Indexed as

global heathinflammationpathogenspulmonary hypertensionpulmonary vascular diseases

Identifiers

PMID39534510
PMCPMC11555293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.